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Information about results and relative benefits is a prerequi- 
site for intelligent choices by payers and consumers as 
well as by the providers of health care. Inadequately 
tested technology and insufficient information about out- -~ 
comes of clinical 
health care. 
When percutaneous 
procedures hamper efforts to improve 
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transluminal coronary angioplasty 
(PTCA) was developed 12 years ago, it was seen as a limited 
technique applicable to no more than 5% to 10% of the 
patients undergoing coronary bypass surgery. However. 
over the last 5 years improvements in angioplasty equipment 
and technique have allowed balloon angioplasty to expand to 
the point where more than 200,000 coronary angioplasties 
were performed in 1988, accounting for more than one half of 
total coronary revascularization procedures (angioplasty or 
bypass surgery) (I ). At the same time, procedural success 
has improved (from 65% to 85%) and the need for emergency 
bypass operations has fallen (from 6% to 2%) (2). even 
though coronary angiolasty is now being applied in progres- 
sively more difficult anatomic and clinical situations. This 
rapid acceptance of coronary angioplasty by the medical 
community has been facilitated by the perception that an- 
gioplasty is (in selected patients) a less invasive and less 
costly means of revascularization than the alternative surgi- 
cal bypass procedure. 
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Limitations of Conventional 
Balloon Angioplasty 
Despite its current overall success, conventional coro- 
nary angioplasty is still troubled by four major problems: 
I) difficulty in crossing some lesions (particularly chronic 
total occlusions) with the guide wire and balloon; 2) difficulty 
in adequately dilmtin~ certain rigid (calcified or fibrotic) or 
elastic (eccentric) lesions; 3) difficulty in preventing or 
reversing intimal dissection and resultant abn4pr closure, 
which can lead to emergency bypass surgery; and 4) diffi- 
culty in reducing the incidence of proliferative restenosis, 
which causes return of angiographic narrowing and ischemic 
symptoms in 257~ to 30% of patients within 6 months of 
initial successful dilation. 
Promising New Technologies 
Convinced that these problems cannot be solved within 
the confines of conventional coronary balloon dilation and 
supported by the venture capital community (itself cognizant 
of the rapid growth of conventional angioplasty), physician- 
inventors have devised a variety of alternative approaches to 
address one or more of these limitations. More than two 
dozen separate devices are now in or approaching clinical 
testing. including 1) aggressive mechanical techniques for 
crossing total occlusions, 2) mechanical atherectomy de- 
vices. 3) athero-abrasion and dispersion catheters, 4) intra- 
coronary stents. 5) ablative laser techniques, and 6) thermal 
techniques (“hot tip” and laser balloon angioplasty). 
Two of us (D.S.B. and K.D.) recently performed a survey 
of interventional cardiologists showing that approximately 
I .OOO coronary procedures had been performed by the end of 
1988 using one of 10 distinct new technology devices. 
Reports presented at the March 1989 meeting of the Amer- 
ican College of Cardiology (3-6) suggest that some of these 
techniques have early results equal to or better than those of 
conventional balloon dilation. However, the evaluation of 
long-term benefit (namely, the restenosis rate) will require 
ongoing performance of late (4 to 6 month) follow-up angi- 
ography. These investigational devices and their concomi- 
tant medical therapy are still undergoing refinement. but it is 
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already clear that one or more of these new techniques will 
play an important role in interventional cardiology, although 
others will offer no proved net advantage over conventional 
balloon dilation. 
Problems to Be Faced in the Device 
Approval Process 
If these new techniques can realize their potential, they 
will allow interventional catheter procedures to be per- 
formed with greater success and safety and account for an 
even larger fraction of revascularization procedures. To be 
adopted, however, any new procedure must receive ap- 
proval from three constituencies: 1) the Food and Drug 
Administration (FDA), 2) the third party payers (led by 
Medicare), and 3) the medical community. How this ap- 
proval process unfolds over the next 2 to 3 years will have 
important consequences for interventional cardiology and, 
in fact, for the cardiac health of our nation. It is not clear that 
traditional FDA protocols (even those currently used to 
evaluate new conventional balloon angioplasty catheters) 
can deal adequately with the simultaneous clinical investi- 
gation of this number of diverse new technologies. 
The Food and Drug Administration 
New devices that entail significant patient risk undergo an 
evaluation process similar to that required for new drugs (7). 
On the basis of laboratory and animal testing, a corporate 
sponsor seeks an Investigational Device Exemption (IDE) to 
perform clinical testing at a limited number of centers 
(usually one or two, including that of the physician- 
inventor). Investigation may begin only after approval of the 
exemption by both the FDA and the Institutional Review 
Board at the participating hospital. If the initial results are 
favorable, the FDA may allow expansion to include more 
centers while the sponsor continues to collect sufficient 
clinical experience to establish safety and efficacy in the eyes 
of the FDA. 
Once enough experience has been collected, the company 
summarizes all preclinical and clinical data in a pre-market 
approval application. This is reviewed by the FDA itself and 
by an “FDA Public Advisory Group” composed primarily of 
physicians. Only after this review (which takes an average of 
1 year [7]) is the device granted a Pre-Market Approval 
allowing general commercial release. Even before Pre- 
Market Approval is granted, however, companies are al- 
lowed to charge participating investigators a “reasonable 
price” (generally $500 to $1,000) for each device based on 
manufacturing costs. 
Current investigations vary as to what aspects of new 
device performance are being evaluated (i.e., success, abil- 
ity to prevent or reverse abrupt closure or ability to prevent 
restenosis), what comparison standards are used (does a 
device have to be better than conventional balloon angio- 
plasty or only “as good”?), and how the comparison to 
conventional balloon angioplasty is made (particularly con- 
sidering that the population treated with most new devices 
includes large numbers of patients at “high risk” for an 
unfavorable outcome with conventional angioplasty and that 
most early trials do not include a conventional angioplasty 
arm). 
Third Party Payers 
When conventional balloon angioplasty was in a devel- 
opmental state (1979 to 1981) similar to that of today’s new 
technology devices, reimbursement was on a “cost” basis. 
This procedure allowed hospitals performing the still inves- 
tigational procedure to receive reimbursement for the overall 
hospitalization (including hospital days and attendant cath- 
eterization and angiography), even though the angioplasty 
procedure itself remained uncovered. By the time the cur- 
rent Medicare system was implemented in 1983, angioplasty 
devices had already received FDA approval, so that coro- 
nary angioplasty became an approved procedure within a 
Diagnosis Related Group (first DRG 108 and later DRG 112) 
(8). Private insurance payers (i.e., Blue Cross) have gener- 
ally provided a similar level of reimbursement, although they 
do not use a DRG system as such. 
No overall policy has been formulated regarding reim- 
bursement for “new technology” procedures during the 
years before they are granted a Pre-Market Approval by the 
FDA. Moreover, FDA approval alone is not sufficient be- 
cause devices must then undergo independent review by the 
Health Care Financing Administration (HCFA) (7). Many 
physicians feel that any percutaneous transluminal proce- 
dure that enlarges a coronary artery lumen is an “angio- 
plasty” and is therefore eligible for reimbursement under 
that code. Thus, new technology procedures might also be 
reimbursable under DRG 112 in patients who otherwise 
would be receiving conventional angioplasty as a clinically 
indicated therapy. 
On the other hand, current Medicare regulations view any 
procedure that uses an investigational device as “experi- 
mental,” with potential denial of all hospitalization claims 
whenever any new technology procedure is performed 
(alone or in conjunction with conventional angioplasty) 
(9). If generalized to other payers, this practice would 
have a chilling effect on current investigation and would 
bring the development of subsequent devices to a virtual 
standstill. The cost of hospitalization would then fall on 
the device sponsor. The companies responsible for new 
technology angioplasty devices are generally single product 
firms working on limited venture capitalization. As a re- 
sult, they are poorly positioned to absorb clinical care 
expenses (approximately $10,000 per patient) for all 
procedures performed before FDA approval, in addition to 
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their substantial engineering, manufacturing and regulatory 
costs. 
The Medical Community 
Ideally, the medical community bases its decisions on 
controlled randomized studies, in this case comparison of 
each new device with conventional balloon angioplasty (or 
possibly with other competing devices), examining safety 
and efficacy against specific problems. Complete studies will 
ultimately be performed, but experience with balloon angio- 
plasty suggests that they may take 5 to 10 years. By that 
time, several devices will have already received FDA ap- 
proval, forcing clinicians to choose among them on the basis 
of less exhaustive data. 
Moreover, interpretation of preliminary results with new 
devices is dificulr because these investigations do not nec- 
essarily involve “mainstream” conventional coronary an- 
gioplasty candidates. Patient selection is based on anatomic 
features that favor successful delivery of prototype devices, 
but it is also skewed strongly toward “high risk” patients 
referred for new technology procedures as alternative treat- 
ment for situations unfavorable to conventional angioplasty 
(multiple prior restenoses, eccentric lesions, vein graft sten- 
oses). In such patients, accurate interpretation of early 
results requires careful reporting utilizing standardized def- 
initions of patient subgroups, short- and long-term results 
and complications. Use of a common definition set is also 
required if results are to be compared with those expected 
from conventional balloon angioplasty in similar patients. 
A Possible Solution 
Although the new technologies for coronary intervention 
offer substantial potential, they come wrapped in some 
difficult problems. Failure to solve these problems effec- 
tively could lead either to premature release of devices that 
offer little additional benefit (and possibly greater risk or 
expense than conventional balloon angioplasty) (lo), or to 
delay in the availability of technologies that have the poten- 
tial to generate annual savings of over $100 million in 
surgical costs for the treatment of abrupt closure and over 
$500 million in subsequent revascularization costs for the 
treatment of restenosis. 
Creation of a registry to collect data on new devices and 
technology. Broader programs for the assessment of new 
medical technology are in the planning stage (lo), but a 
possible shorter-term solution entails creation of a registry 
devoted to the collection of information on new technology 
coronary angioplasty, analogous to the National Heart, 
Lung, and Blood Institute-sponsored PT’CA Registries I 
(1979 to 1981) and II (1985 to 1986) (2), which played such an 
instrumental role in facilitating the understanding and accep- 
tance of conventional balloon angioplasty. Devices would be 
eligible for inclusion once they had moved to the multicenter 
level and could continue to participate until receipt of 
Pre-Market Approval. Baseline clinical and angiographic 
data, procedural success and complications, and follow-up 
data would be collected using similar definitions for all 
participating devices, although the procedure description 
would be unique to each device. Such a registry would allow 
easy understanding of results with each device, and would 
permit comparison with conventional balloon angioplasty in 
an appropriate group of patients from the prior registries. 
The results of one device could also be compared with those 
of another, using similar definitions and carefully selected 
matched patient subgroups (i.e., mid-graft lesions, more 
than 1 year postsurgical bypass). 
Primary access to registry data could be restricted to the 
group of physicians (and the corporate sponsor) investigat- 
ing each device, although data could be submitted to the 
FDA by the sponsor in parallel. Investigator and sponsor 
approval would be required before comparisons could be 
made with conventional angioplasty or other consenting 
devices. 
Although it may be reasonable to ask corporate sponsors 
to bear part of the cost of initial cases, devices might then be 
granted provisional third party payer approval for reim- 
bursement at a level equivalent to that of conventional 
angioplasty, if they could substantiate “angioplasty- 
equivalent” results after treating specified numbers of pa- 
tients (i.e., 100, 250 and 500 patients). Devices not meeting 
these agreed upon performance levels could be placed on 
probationary funding status until changes in device design or 
protocol bring results into line. In this way, third party payer 
expenses would not exceed those of an equivalent number of 
clinically indicated conventional angiolasty procedures, al- 
though the third parties would benefit by participating in the 
collection of the quality data needed to make intelligent 
choices among the several potentially beneficial and cost- 
saving new technologies. 
Recommendations. We believe that the problems of new 
technology coronary angioplasty are sufficiently pressing to 
warrant the creation of a multicenter registry as our best 
opportunity to perform controlled, high quality investigation 
of promising new angioplasty technologies at a reasonable 
pace without jeopardizing either patient safety or health care 
costs. However, for this approach to be taken, preparations 
must begin immediately because new technology coronary 
procedures are now being performed at a rapidly accelerat- 
ing pace. Once a suitable registry has been created, addi- 
tional infrastructure (including channels of communication 
among device sponsors, investigators, the FDA and the 
HCFA) and a participatory reimbursement scheme (for what 
already exceeds $10 million in clinical care costs) must be 
established. 
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